StockNews.AI
RVTY
StockNews.AI
43 days

Revvity to Hold Earnings Call on Monday, July 28, 2025

1. Revvity will release Q2 2025 financial results on July 28, 2025. 2. A conference call will discuss these results at 8:00 a.m. ET. 3. Revvity generated over $2.7 billion in revenue in 2024. 4. The company has a significant global presence with 11,000 employees. 5. Revvity is part of the S&P 500 index, which indicates stability.

Earnings
-0.37%Current Return
VS
-0.65%S&P 500
$101.3107/07 08:14 AM EDTEvent Start
$100.9407/08 02:14 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results could show positive growth trends, boosting RVTY stock. Historical performance of companies releasing strong quarterly results suggests positive price movements.

How important is it?

The upcoming earnings call is critical for RVTY investors anticipating performance indicators. Strong revenue figures could enhance investor confidence and attract new buyers.

Why Short Term?

Financial results are imminent; thus, any significant impact will be short-term. Similar past events have led to immediate stock price fluctuations based on earnings.

Related Companies

SPYXLVAMGNBDXILMN
- WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2025 financial results prior to market open on Monday, July 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries. Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram. More News From Revvity

Related News